29 May 2019 - Imara today announced that the U.S. FDA has granted fast track designation to IMR-687, the company’s lead product candidate for the treatment of sickle cell disease.
IMR-687 is currently being evaluated in a multi-national Phase 2a clinical trial in adult patients.